Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Kesmalea Therapeutics ApS
APS
In liquidation
CVR 41804505
Amaliegade 37, 1256
København K
Forskning og eksperimentel udvikling indenfor bioteknologi
· NACE 721100
Est. 2020
— employees
Watchlist
Share
Denmark
/
Companies
/
Forskning og eksperimentel udvikling indenfor bioteknologi
/
Kesmalea Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
DKK millions
0M
-1M
-2M
-3M
-3M
-3M
2021
EBITDA
DKK millions
0M
-1M
-2M
-3M
-3M
-3M
2021
Income statement
DKK thousands
Item
2021
Revenue
-3.111
Staff expenses
-0
EBITDA
-3.111
Depreciation & amort.
-0
EBIT
-3.111
Net financials
-204
Profit before tax
-3.314
Tax
-0
Net profit
-3.314
Balance sheet
DKK thousands
Item
2021
Total assets
427
Equity
-3.274
Long-term debt
3.687
Short-term debt
15
Total debt
3.702
Financial ratios
5-year trend
EBITDA margin
-311071500.0%
This company
15.8%
Market median
-1968807062% vs market
2021
2021
Equity ratio
-766.3%
This company
38.2%
Market median
-2106% vs market
2021
2021
Return on equity
-331439500.0%
This company
18.4%
Market median
-1801301730% vs market
2021
2021
Net profit margin
-331439500.0%
This company
8.1%
Market median
-4091845779% vs market
2021
2021
Asset turnover
-7.28×
This company
1.12×
Market median
-750% vs market
2021
2021
Debt / equity
1.13×
This company
0.62×
Market median
-82% vs market
2021
2021
Annual reports & filings
Annual report 2021
Filed via CVR / Virk · Period 2020-10-28 – 2021-12-31
View
PDF
More on Kesmalea Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
